Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Return on Equity (2018 - 2025)

VYNE Therapeutics (VYNE) has disclosed Return on Equity for 8 consecutive years, with 0.0% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity changed 0.0% year-over-year to 0.0%, compared with a TTM value of 0.0% through Dec 2025, changed 0.0%, and an annual FY2025 reading of 0.01%, up 1.0% over the prior year.
  • Return on Equity was 0.0% for Q4 2025 at VYNE Therapeutics, down from 0.0% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.3% in Q4 2022 and bottomed at 3.45% in Q1 2021.
  • Average Return on Equity over 5 years is 0.29%, with a median of 0.01% recorded in 2024.
  • Peak annual rise in Return on Equity hit 533bps in 2021, while the deepest fall reached -69bps in 2021.
  • Year by year, Return on Equity stood at 0.54% in 2021, then soared by 156bps to 0.3% in 2022, then plummeted by -104bps to 0.01% in 2023, then surged by 96bps to 0.0% in 2024, then crashed by -54bps to 0.0% in 2025.
  • Business Quant data shows Return on Equity for VYNE at 0.0% in Q4 2025, 0.0% in Q2 2025, and 0.0% in Q1 2025.